General Clinical Chemistry Analyzers and Accessories
Abcam GW-311616A, 5MG
MW 434 Da, Purity >=98%. A potent and selective intracellular neutrophil elastase (NE, alpha-1-proteinase) inhibitor. Inhibits human neutrophil elastase (HNE) and is selective over other human serine proteases with IC₅₀ values of 22 nM for HNE, >100 μM for trypsin, cathepsin G and plasmin, >3 μM for chymotrypsin and tissue plasminogen activator.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IMR-1, 25MG
MW 353.4 Da, Purity =99%. Notch pathway inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WH-4-023, 5MG
MW 568.7 Da, Purity >98%. Potent and selective inihbitor of the tyrosine kinases Lck and Src with IC₅₀ values of 2 nM for Lck and 6 nM for Src.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Capivasertib (AZD5363), 100MG
MW 428.9 Da, Purity >95%. A novel pyrrolopyrimidine derivative. A potent inhibitor of all AKT isoforms, IC₅₀ <10 nM, with potential antineoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Apatinib, 25MG
MW 441.9 Da. Potent and selective inhibitor of VEGFR2, IC₅₀ = 1 nm. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML-385, 5MG
MW 511.6 Da, Purity >=98%. A potent and selective Nrf2 inhibitor (Nrf2; IC₅₀ = 1.9 μM). ML-385 blocks Nrf2 downstream target gene expression. ML-385 displays specificity and selectivity for NSCLC cells with KEAP1 mutation, which leads to gain of Nrf2 function.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V-9302, 1MG
MW 538.7 Da, Purity >=98%. A competitive antagonist of transmembrane glutamine flux, that selectively targets the amino acid transporter ASCT2 (SLC1A5). V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀ = 9.6 μM) in HEK-293 cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V-9302, 5MG
MW 538.7 Da, Purity >=98%. A competitive antagonist of transmembrane glutamine flux, that selectively targets the amino acid transporter ASCT2 (SLC1A5). V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀ = 9.6 μM) in HEK-293 cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam E7820, 25MG
MW 336.4 Da, Purity >=98%. A small molecule sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 7-(Diethylamino)coumarin-3-carbonyl azide, 25MG
MW 286.29 Da, Purity >95%. Aldehyde and ketone reactive probe. Suitable for labeling proteins and other carbonyl-containing molecules. Ceramides can be derivatized using 7-(diethylamino)coumarin-3-carbonyl azide with subsequent gradient HPLC separation allowing sensitive optical quantification of individual cellular ceramides. Suitable for use in HPLC labeling of lipids and alkylcycloketones.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 50MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 50MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TW-37, 25MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Alvespimycin (17-DMAG) hydrochloride, 100MG
MW 653.2 Da, Purity >99%. A potent Hsp90 inhibitor (IC₅₀ = 62 nM), can bind to the ATP-binding motif and inhibit the protein chaperoning activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ispinesib (SB-715992), 100MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement